CoChat

Eszopiclone for insomnia

Open access
Rösner, Susanne, Englbrecht, Christian, Wehrle, Renate, Hajak, Göran, Soyka, Michael · 2018 · Cochrane Database of Systematic Reviews
Cited by 54

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Insomnia is a major public health issue affecting between 6% to 10% of the adult population in Western countries. Eszopiclone is a hypnotic drug belonging to a newer group of hypnotic agents, known as new generation hypnotics, which was marketed as being just as effective as benzodiazepines for this condition, while being safer and having a lower risk for abuse and dependence. It is the aim of the review to integrate evidence from randomised controlled trials and to draw conclusions on eszopiclone's efficacy and safety profile, while taking methodological features and bias risks into consideration. OBJECTIVES: To assess the efficacy and safety of eszopiclone for the treatment of insomnia compared to placebo or active control. SEARCH METHODS: We searched the Cochrane Central Register of Controlled trials (CENTRAL), MEDLINE, Embase, PsycINFO, PSYNDEX and registry databases (WHO trials portal, ClinicalTrials.gov) with results incorporated from searches to 10 February 2016. To identify trials not registered in electronic databases, we contacted key informants and searched reference lists of identified studies. We ran an update search (21 February 2018) and have placed studies of interest in awaiting classification/ongoing studies. These will be incorporated into the next version of the review, as appropriate. SELECTION CRITERIA: Parallel group randomised controlled trials (RCTs) comparing eszopiclone with either placebo or active control were included in the review. Participants were adults with insomnia, as diagnosed with a standardised diagnostic system, including primary insomnia and comorbid insomnia. DATA COLLECTION AND ANALYSIS: Two authors independently extracted outcome data; one reviewer assessed trial quality and the second author cross-checked it. MAIN RESULTS: A total of 14 RCTs, with 4732 participants, were included in this review covering short-term (≤ 4 weeks; 6 studies), medium-term (> 4 weeks ≤ 6 months; 6 studies) and long-term treatment (> 6 months; 2 studies) with eszopiclone. Most RCTs included in the review included participants aged between 18 and 64 years, three RCTs only included elderly participants (64 to 85 years) and one RCT included participants with a broader age range (35 to 85 years). Seven studies considered primary insomnia; the remaining studies considered secondary insomnia comorbid with depression (2), generalised anxiety (1), back pain (1), Parkinson's disease (1), rheumatoid arthritis (1) and menopausal transition (1).Meta-analytic integrations of participant-reported data on sleep efficacy outcomes demonstrated better results for eszopiclone compared to placebo: a 12-minute decrease of sleep onset latency (mean difference (MD) -11.94 min, 95% confidence interval (CI) -16.03 to -7.86; 9 studies, 2890 participants, moderate quality evidence), a 17-minute decrease of wake time after sleep onset (MD -17.02 min, 95% CI -24.89 to -9.15; 8 studies, 2295 participants, moderate quality evidence) and a 28-minute increase of total sleep time (MD 27.70 min, 95% CI 20.30 to 35.09; 10 studies, 2965 participants, moderate quality evidence). There were no significant changes from baseline to the first three nights after drug discontinuation for sleep onset latency (MD 17.00 min, 95% CI -4.29 to 38.29; 1 study, 291 participants, low quality evidence) and wake time after sleep onset (MD -6.71 min, 95% CI -21.25 to 7.83; 1 study, 291 participants, low quality evidence). Adverse events during treatment that were documented more frequently under eszopiclone compared to placebo included unpleasant taste (risk difference (RD) 0.18, 95% CI 0.14 to 0.21; 9 studies, 3787 participants), dry mouth (RD 0.04, 95% CI 0.02 to 0.06; 6 studies, 2802 participants), somnolence (RD 0.04, 95% CI 0.02 to 0.06; 8 studies, 3532 participants) and dizziness (RD 0.03, 95% CI 0.01 to 0.05; 7 studies, 2933 participants). According to the GRADE criteria, evidence was rated as being of moderate quality for sleep efficacy outcomes and adverse events and of low quality for rebound effects and next-day functioning. AUTHORS' CONCLUSIONS: Eszopiclone appears to be an efficient drug with moderate effects on sleep onset and maintenance. There was no or little evidence of harm if taken as recommended. However, as certain patient subgroups were underrepresented in RCTs included in the review, findings might not have displayed the entire spectrum of possible adverse events. Further, increased caution is required in elderly individuals with cognitive and motor impairments and individuals who are at increased risk of using eszopiclone in a non-recommended way.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd010703.pub2

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Research works printed but not linked: 140

  1. Ancoli-Israel, 2010, A 12-week, randomised, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia, Sleep, 33, 225, 10.1093/sleep/33.2.225 · DOI · Paper page
  2. Goforth, 2014, A randomised, double-blind, placebo-controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain, Sleep, 37, 1053, 10.5665/sleep.3760 · DOI
  3. McCall, 2006, A polysomnography study of eszopiclone in elderly patients with insomnia, Current Medical Research and Opinion, 22, 1633, 10.1185/030079906X112741 · DOI · Paper page
  4. McCall, 2010, Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self reported sleep, and depression, Journal of Clinical Sleep Medicine, 6, 322, 10.5664/jcsm.27872 · DOI
  5. Menza, 2010, Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo, Movement Disorders, 25, 1708, 10.1002/mds.23168 · DOI · Paper page
  6. Pollack, 2008, Eszopiclone co-administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder, Archives of General Psychiatry, 65, 551, 10.1001/archpsyc.65.5.551 · DOI · Paper page
  7. Roth, 2009, The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study, Primary Care Companion to the Journal of Clinical Psychiatry, 11, 292, 10.4088/PCC.08m00749bro · DOI
  8. Scharf, 2005, A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia, Sleep, 28, 720, 10.1093/sleep/28.6.720 · DOI · Paper page
  9. Spierings, 2015, Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double-blind, placebo-controlled, parallel-group, pilot study, Cranio, 33, 115, 10.1179/0886963414Z.00000000084 · DOI
  10. Zammit, 2004, Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia, Current Medical Research and Opinion, 20, 1979, 10.1185/174234304X15174 · DOI · Paper page
  11. Attarian, 2011, Effect of eszopiclone on sleep disturbances and daytime fatigue in multiple sclerosis patients, International Journal of MS Care, 13, 84, 10.7224/1537-2073-13.2.84 · DOI
  12. Boyle, 2008, Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone, Human Psychopharmacology, 23, 385, 10.1002/hup.936 · DOI · Paper page
  13. Boyle, 2012, A method to assess the dissipation of residual hypnotics: eszopiclone versus zopiclone, Journal of Clinical Psychopharmacology, 32, 704, 10.1097/JCP.0b013e3182664eec · DOI
  14. Dimsdale, 2011, Effect of eszopiclone on sleep, fatigue, and pain in patients with mucositis associated with hematologic malignancies, Supportive Care in Cancer, 19, 2015, 10.1007/s00520-010-1052-1 · DOI
  15. Erman, 2008, A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia, Journal of Clinical Sleep Medicine, 4, 229, 10.5664/jcsm.27185 · DOI
  16. Huang, 2015, Sleep disorder of schizophrenia treated with shallow needling: a randomised controlled trial, Zhongguo Zhenjiu, 35, 869
  17. Lettieri, 2008, Eszopiclone improves overnight polysomnography and continuous positive airway pressure titration: a prospective, randomized, placebo-controlled trial, Sleep, 31, 1310
  18. Peng, 2013, Efficacy of eszopiclone combined with psychotherapy in the treatment of insomnia, Chinese Journal of New Drugs, 22, 443
  19. Pollack, 2011, Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomised, double-blind, placebo-controlled trial, Journal of Clinical Psychiatry, 72, 892, 10.4088/JCP.09m05607gry · DOI · Paper page
  20. Rosenberg, 2005, An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults, Sleep Medicine, 6, 15, 10.1016/j.sleep.2004.09.001 · DOI
  21. Rosenberg, 2007, A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome, Sleep Medicine, 8, 464, 10.1016/j.sleep.2006.10.007 · DOI
  22. Sangal, 2014, Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder, Pediatrics, 134, 1095, 10.1542/peds.2013-4221 · DOI
  23. Uchimura, 2012, Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and non-elderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomised, double-blind study, Annals of General Psychiatry, 25, 2
  24. Uchimura, 2012, A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia, Sleep Med, 13, 1247, 10.1016/j.sleep.2012.08.015 · DOI
  25. Baran B Demanuele C Vuper TC The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a double-blind randomised trial Sleep Conference: 31st Anniversary Meeting of the Associated Professional Sleep Societies, LLC, SLEEP United States 2017 A415 · DOI
  26. Buxton, 2017, Lack of change in glucose metabolism in eszopiclone-treated primary insomnia patients, Nature and Science of Sleep, 9, 187, 10.2147/NSS.S130505 · DOI
  27. Pinto LR Jr Bittencourt LR Treptow EC Braga LR Tufik S Eszopiclone versus zopiclone in the treatment of insomnia Clinics (Sao Paulo) 2016 5 9 · DOI
  28. American Academy of Sleep, 2014, International Classification of Sleep Disorders: Diagnostic and Coding Manual, ICSD-3
  29. American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders, DSM-5, 10.1176/appi.books.9780890425596 · DOI · Paper page
  30. Angst, 1989, The Zurich Study. VII. Insomnia: symptoms, classification and prevalence, European Archives of Psychiatry and Neurological Sciences, 238, 285, 10.1007/BF00449810 · DOI
  31. Arnedt, 2007, Treatment options for sleep disturbances during alcohol recovery, Journal of Addictive Diseases, 26, 41, 10.1300/J069v26n04_06 · DOI · Paper page
  32. Ballenger, 2000, Benzodiazepine receptor agonists and antagonists
  33. Barbone, 1998, Association of road-traffic accidents with benzodiazepine use, Lancet, 352, 1331, 10.1016/S0140-6736(98)04087-2 · DOI · Paper page
  34. Bastien, 2004, Precipitating factors of insomnia, Behavioral Sleep Medicine, 2, 50, 10.1207/s15402010bsm0201_5 · DOI · Paper page
  35. Bateson, 2004, The benzodiazepine site of the GABAA receptor: an old target with new potential?, Sleep Medicine, 5, 9, 10.1016/S1389-9457(04)90002-0 · DOI
  36. Ben-Hamou, 2011, Spontaneous adverse event reports associated with zolpidem in Australia 2001-2008, Journal of Sleep Research, 20, 559, 10.1111/j.1365-2869.2011.00919.x · DOI · Paper page
  37. Berry, 2013, Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents, JAMA Internal Medicine, 173, 754, 10.1001/jamainternmed.2013.3795 · DOI · Paper page
  38. Bertisch, 2014, National use of prescription medications for insomnia: NHANES 1999-2010, Sleep, 37, 343, 10.5665/sleep.3410 · DOI · Paper page
  39. Botteman, 2007, Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model, CNS Drugs, 21, 319, 10.2165/00023210-200721040-00005 · DOI
  40. Brower, 2001, Insomnia, self-medication, and relapse to alcoholism, American Journal of Psychiatry, 158, 399-404, 10.1176/appi.ajp.158.3.399 · DOI · Paper page
  41. Brunello, 2008, Pharmacokinetics of (S)-zopiclone and (S)-desmethylzopiclone following dosing with zopiclone and eszopiclone, Neuropsychopharmacology, 18, 581, 10.1016/S0924-977X(08)70890-3 · DOI
  42. Brunette, 2003, Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders, Psychiatric Services, 54, 1395, 10.1176/appi.ps.54.10.1395 · DOI · Paper page
  43. Buysse, 2011, A neurobiological model of insomnia, Drug Discovery Today: Disease Models, 8, 129
  44. Cape, 2015, Group cognitive behavioural treatment for insomnia in primary care: a randomised controlled trial, Psychological Medicine, 16, 1
  45. Cappuccio, 2011, Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies, European Heart Journal, 32, 1484, 10.1093/eurheartj/ehr007 · DOI · Paper page
  46. Cimolai, 2007, Zopiclone. Is it a pharmacologic agent for abuse?, Canadian Family Physician, 53, 2124
  47. Conroy, 2006, Perception of sleep in recovering alcohol-dependent patients with insomnia: relationship with future drinking, Alcoholism: Clinical and Experimental Research, 30, 1992, 10.1111/j.1530-0277.2006.00245.x · DOI · Paper page
  48. Delahaye, 1990, Post marketing surveillance of zopiclone: interim analysis on the first 10,000 cases in a clinical study in general practice, International Clinical Psychopharmacology, 5 Suppl, 131
  49. DerSimonian, 1986, Meta-analysis in clinical trials, Controlled Clinical Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  50. Diem, 2014, Use of non-benzodiazepine sedative hypnotics and risk of falls in older men, Journal of Gerontology & Geriatric Research, 3, 158, 10.4172/2167-7182.1000158 · DOI
  51. Dolder, 2007, Use of non-benzodiazepine hypnotics in the elderly: are all agents the same?, CNS Drugs, 21, 389, 10.2165/00023210-200721050-00003 · DOI
  52. Drover, 2000, Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem, Clinical Therapeutics, 22, 1443, 10.1016/S0149-2918(00)83043-X · DOI · Paper page
  53. Drover, 2004, Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone, Clinical Pharmacokinetics, 43, 227, 10.2165/00003088-200443040-00002 · DOI · Paper page
  54. Dündar, 2004, Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis, Human Psychopharmacology, 19, 305, 10.1002/hup.594 · DOI · Paper page
  55. Dündar, 2004, Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation, Health Technology Assessment, 8, iii-x, 1-125, 10.3310/hta8240 · DOI · Paper page
  56. Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, British Medical Journal, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  57. Elko, 1998, Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction., Journal of Toxicology: Clinical Toxicology, 36, 195-203
  58. Erman, 2004, Polysomnographic and patient-reported evaluation of the efficacy and safety of eszopiclone in elderly subjects with chronic insomnia, Sleep, 27 Suppl, 257
  59. Erman, 2005, Therapeutic options in the treatment of insomnia, Journal of Clinical Psychiatry, 66, 18
  60. Fava, 2011, A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression, Journal of Clinical Psychiatry, 72, 473, 10.4088/JCP.09m05131gry · DOI · Paper page
  61. Finkle, 2011, Risk of fractures requiring hospitalisation after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults, Journal of the American Geriatrics Society, 59, 1883, 10.1111/j.1532-5415.2011.03591.x · DOI · Paper page
  62. Follesa, 2002, Changes in GABA(A) receptor gene expression induced by withdrawal of, but not by long-term exposure to, zaleplon or zolpidem, Neuropharmacology, 42, 191, 10.1016/S0028-3908(01)00167-8 · DOI
  63. Fortier-Brochu, 2012, Insomnia and daytime cognitive performance: a meta-analysis, Sleep Medicine Reviews, 16, 83, 10.1016/j.smrv.2011.03.008 · DOI · Paper page
  64. Foster, 1999, Impaired sleep in alcohol misusers and dependent alcoholics and the impact upon outcome, Alcoholism: Clinical and Experimental Research, 23, 1044-51, 10.1111/j.1530-0277.1999.tb04223.x · doi:10.1111/j.1530-0277.1999.tb04223.x · Paper page
  65. Friedmann, 2003, Treatment of sleep disturbance in alcohol recovery: a national survey of addiction medicine physicians, Journal of Addictive Diseases, 22, 91, 10.1300/J069v22n02_08 · DOI · Paper page
  66. Greenblatt, 1981, Benzodiazepines. A summary of pharmacokinetic properties, British Journal of Clinical Pharmacology, 11, 11, 10.1111/j.1365-2125.1981.tb01833.x · DOI · Paper page
  67. Hajak, 1997, Psychological, psychotherapeutic and other non-pharmacologic forms of therapy in treatment of insomnia, Fortschritte der Neurologie-Psychiatrie, 65, 133, 10.1055/s-2007-996317 · doi:10.1055/s-2007-996317
  68. Hajak, 2002, Zolpidem "as needed" versus continuous administration: Pan-European study results, Sleep Med Rev, 6, 21, 10.1016/S1087-0792(02)80004-1 · DOI
  69. Hamilton, 1959, The assessment of anxiety states by rating, Br J Med Psychol, 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
  70. Hamiltion, 1960, A rating scale for depression, Journal of Neurology, Neurosurgery & Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  71. Harvey, 2014, Who is predisposed to insomnia: a review of familial aggregation, stress-reactivity, personality and coping style, Sleep Med Rev, 18, 237, 10.1016/j.smrv.2013.11.004 · DOI · Paper page
  72. Hausken, 2009, Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors, European Journal of Clinical Pharmacology, 65, 295, 10.1007/s00228-008-0565-8 · DOI
  73. Higgins, 2003, Measuring inconsistency in meta-analyses, British Medical Journal, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  74. Higgins JPT Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org 2011 243 96
  75. Hoffmann, 2009, Use of zolpidem and zopiclone on private prescriptions between 1993 and 2007, Der Nervenarzt, 80, 578, 10.1007/s00115-008-2648-2 · DOI
  76. Hoffmann, 2014, Benzodiazepine hypnotics, zolpidem and zopiclone on private prescriptions: use between 1993 and 2012, Der Nervenarzt, 85, 1402, 10.1007/s00115-014-4016-8 · DOI
  77. Hozo, 2005, Estimating the mean and variance from the median, range, and the size of a sample, BMC Medical Research Methodology, 20, 1
  78. Jaffe, 2004, A post-marketing study of relative abuse liability of hypnotic sedative drugs, Addiction, 99, 165, 10.1111/j.1360-0443.2003.00631.x · DOI · Paper page
  79. Johnson, 2001, Sleep problems and substance use in adolescence., Drug and Alcohol Dependence, 64, 1, 10.1016/S0376-8716(00)00222-2 · DOI · Paper page
  80. Kaplan, 2014, An evidence-based review of insomnia treatment in early recovery, Journal of Addiction Medicine, 8, 389, 10.1097/ADM.0000000000000052 · DOI
  81. Krishnan, 2011, A call for action: comparative effectiveness research in asthma, Journal of Allergy and Clinical Immunology, 127, 123, 10.1016/j.jaci.2010.08.032 · DOI
  82. Krystal, 2007, Evaluation of eszopiclone discontinuation after co-therapy with fluoxetine for insomnia with coexisting depression, Journal of Clinical Sleep Medicine, 3, 48, 10.5664/jcsm.26745 · DOI · Paper page
  83. Krystal, 2012, A WASO sub-group analysis of a 6-month study of eszopiclone 3 mg, Sleep Medicine, 13, 691, 10.1016/j.sleep.2012.01.010 · DOI
  84. Lader, 1999, Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?, European Neuropsychopharmacology, 9, 399, 10.1016/S0924-977X(99)00051-6 · DOI · Paper page
  85. Lerner, 2001, The Work Limitations Questionnaire, Medical Care, 39, 72, 10.1097/00005650-200101000-00009 · DOI · Paper page
  86. Leshner A NIH State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults NIH Consensus and State-of-the-Science Statements 2005 1 30 · DOI
  87. Li, 2014, Association between insomnia symptoms and mortality: a prospective study of U.S. men, Circulation, 129, 737, 10.1161/CIRCULATIONAHA.113.004500 · DOI · Paper page
  88. Licata, 2008, A therapeutic dose of zolpidem has limited abuse-like effects in drug-naïve females: a pilot study, European Journal of Pharmacology, 598, 64, 10.1016/j.ejphar.2008.09.011 · DOI
  89. Lingford-Hughes, 2002, Imaging the GABA-benzodiazepine receptor subtype containing the alpha 5-subunit in vivo with (11C)Ro15 4513 positron emission tomography, Journal of Cerebral Blood Flow and Metabolism, 22, 878-88, 10.1097/00004647-200207000-00013 · DOI · Paper page
  90. Maier, 1985, Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale, Pharmacopsychiatry, 18, 114, 10.1055/s-2007-1017335 · DOI
  91. Mantel, 1959, Statistical aspects of the analysis of data from retrospective disease, Journal of the National Cancer Institute, 22, 719-48
  92. McCall, 2009, Eszopiclone at bedtime improves the quality of life in depressed insomniacs receiving fluoxetine, Sleep, 32, A348
  93. McCall, 2010, Insomnia severity is an indicator of suicidal ideation during a depression clinical trial, Sleep Medicine, 11, 822, 10.1016/j.sleep.2010.04.004 · DOI · Paper page
  94. McCall, 2011, Dissection of the factors driving the placebo effect in hypnotic treatment of depressed insomniacs, Sleep Medicine, 12, 557, 10.1016/j.sleep.2011.03.008 · DOI
  95. McCall, 2011, Both actigraphy data and the intensity of insomnia complaints differ between suicidal and non-suicidal depressed patients enrolled in a hypnotic clinical trial, Journal of Sleep Research, 20, 24
  96. McCall, 2012, Objective vs. subjective measurements of sleep in depressed insomniacs: first night effect or reverse first night effect?, Journal of Clinical Sleep Medicine, 15, 59, 10.5664/jcsm.1664 · DOI
  97. Melton, 2005, Eszopiclone for insomnia, Annals of Pharmacotherapy, 39, 1659, 10.1345/aph.1G179 · DOI
  98. Metlaine, 2005, Socioeconomic impact of insomnia in working populations, Industrial Health, 43, 11, 10.2486/indhealth.43.11 · DOI · Paper page
  99. Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLOS Medicine, 6, e1000097, 10.1371/journal.pmed.1000097 · DOI · Paper page
  100. Monti, 2007, Eszopiclone: its use in the treatment of insomnia, Neuropsychiatric Disease and Treatment, 3, 441
  101. Montplaisir, 2003, Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement, Human Psychopharmacology, 18, 29, 10.1002/hup.445 · DOI
  102. Najib, 2006, Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia, Clinical Therapeutics, 28, 491, 10.1016/j.clinthera.2006.04.014 · DOI
  103. Nickerson, 1998, Confirmation bias: a ubiquitous phenomenon in many guises, Review of General Psychology, 2, 175-220, 10.1037/1089-2680.2.2.175 · DOI · Paper page
  104. Palagini, 2014, The genetics of insomnia--evidence for epigenetic mechanisms?, Sleep Med Rev, 18, 225, 10.1016/j.smrv.2013.05.002 · DOI
  105. Parthasarathy, 2015, Persistent insomnia is associated with mortality risk, American Journal of Medicine, 128, 268, 10.1016/j.amjmed.2014.10.015 · DOI · Paper page
  106. Pildal, 2007, Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials, International Journal of Epidemiology, 36, 847, 10.1093/ije/dym087 · DOI · Paper page
  107. Ramakrishnan, 2007, Treatment options for insomnia, American Family Physician, 76, 517
  108. Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014
  109. Riemann, 2009, Functional and structural brain alterations in insomnia: implications for pathophysiology, European Journal of Neuroscience, 29, 1754, 10.1111/j.1460-9568.2009.06721.x · DOI
  110. Riemann, 2014, Insomnia - state of the science, Der Nervenarzt, 85, 43, 10.1007/s00115-013-3892-7 · DOI
  111. Riemann, 2015, The neurobiology, investigation, and treatment of chronic insomnia, Lancet Neurolology, 14, 547, 10.1016/S1474-4422(15)00021-6 · DOI · Paper page
  112. Roane, 2008, Adolescent insomnia as a risk factor for early adult depression and substance abuse, Sleep, 31, 1351
  113. Rosekind, 2010, Insomnia risks and costs: health, safety, and quality of life, American Journal of Managed Care, 16, 617
  114. Roth, 2003, Insomnia: epidemiology, characteristics, and consequences, Clinical Cornerstone, 5, 5, 10.1016/S1098-3597(03)90031-7 · DOI · Paper page
  115. Roth, 2009, Sleep duration, insomnia and longevity, Sleep Medicine, 10, 1071, 10.1016/j.sleep.2009.04.004 · DOI
  116. Rösner, 2013, Zolpidem for insomnia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD010700 · DOI
  117. Rösner, 2013, Zopiclone for insomnia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD010701 · DOI
  118. Rösner, 2013, Zaleplon for insomnia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD010702 · DOI
  119. Scharf, 2006, Eszopiclone for the treatment of insomnia, Expert Opinion in Pharmacotherapy, 7, 345, 10.1517/14656566.7.3.345 · DOI
  120. Schnitzer T Rubens R Price The effect of eszopiclone 3 mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia American College of Rheumatology Conference; 2005 November 12-17; 2005; San Diego (poster) 2005
  121. Schulz, 1995, Subverting randomization in controlled trials, Journal of the American Medical Association, 274, 1456, 10.1001/jama.1995.03530180050029 · DOI · Paper page
  122. Shekleton, 2010, Searching for the daytime impairments of primary insomnia, Sleep Medicine Reviews, 14, 47, 10.1016/j.smrv.2009.06.001 · DOI · Paper page
  123. Sieghart, 2006, Structure, pharmacology, and function of GABAA receptor subtypes, Advances in Pharmacology, 54, 231, 10.1016/S1054-3589(06)54010-4 · DOI · Paper page
  124. Siriwardena, 2008, Magic bullets for insomnia? Patients' use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care, British Journal of General Practice, 58, 417, 10.3399/bjgp08X299290 · DOI · Paper page
  125. Snedecor, 2009, Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia, Sleep, 32, 817, 10.1093/sleep/32.6.817 · DOI
  126. Soyka, 2000, Epidemiological evidence for a low abuse potential of zolpidem, Pharmacopsychiatry, 33, 138, 10.1055/s-2000-11224 · DOI · Paper page
  127. Spielman, 1991, The varied nature of insomnia, 1, 10.1007/978-1-4757-9586-8_1 · DOI
  128. Stebbing, 2005, Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective study, Journal of Clinical Oncology, 23, 8134, 10.1200/JCO.2005.03.5881 · DOI
  129. Toner, 2000, Central nervous system side effects associated with zolpidem treatment, Clinical Neuropharmacology, 23, 54, 10.1097/00002826-200001000-00011 · DOI · Paper page
  130. Tsai, 2003, A novel clinical pattern of visual hallucination after zolpidem use, Journal of Toxicology: Clinical Toxicology, 41, 869-72
  131. Vallières, 2005, Variability and predictability in sleep patterns of chronic insomniacs, Journal of Sleep Research, 14, 447, 10.1111/j.1365-2869.2005.00480.x · DOI · Paper page
  132. Victorri-Vigneau, 2014, An update on zolpidem abuse and dependence, Journal of Addictive Diseases, 33, 15, 10.1080/10550887.2014.882725 · DOI · Paper page
  133. Voderholzer, 2001, A double-blind, randomised and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects, European Archives of Psychiatry and Clinical Neuroscience, 251, 117, 10.1007/s004060170045 · DOI
  134. Wang, 2001, Zolpidem use and hip fractures in older people, Journal of the American Geriatrics Society, 49., 1685, 10.1111/j.1532-5415.2001.49280.x · DOI · Paper page
  135. Ware, 1992, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med Care, 30, 473, 10.1097/00005650-199206000-00002 · DOI · Paper page
  136. Wechsler, 1955, Manual for the Wechsler scale
  137. Winkelman, 2015, Insomnia, N Engl J Med, 373, 1437, 10.1056/NEJMcp1412740 · DOI · Paper page
  138. World Health Organization, 1992, The ICD-10 Classification of Mental and Behavioural Disorders
  139. Zammit, 1999, Quality of life in people with insomnia, Sleep, 22, 379
  140. Rösner, 2013, Eszopiclone for insomnia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD010703 · DOI

Cited by

See all 54

Metadata

Authors
Rösner, S., Englbrecht, C., Wehrle, R., Hajak, G., & Soyka, M.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2018-10-10
Volume
2018
Issue
10
Pages
CD010703-CD010703
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1791492057
Cited by
54
References
59
FWCI
4.94
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Eszopiclone for insomnia. https://app.cochat.ai/papers/10.1002/14651858.cd010703.pub2
The paper
Rösner, S., Englbrecht, C., Wehrle, R., Hajak, G., & Soyka, M. (2018). Eszopiclone for insomnia. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd010703.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.